CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishPURPOSE: The aim of the present study was to assess serum lipid levels before and after treatment with oxcarbazepine in children with epilepsy. METHODS: We measured total cholesterol (TC), triglycerides (TGs) and high-density lipoprotein cholesterol (HDL-C) in 28 patients whereas only TC levels in 11 patients, during baseline period and at 3 months after the beginning of therapy with oxcarbazepine. RESULTS: During baseline period, median values were: 4.38 (IQR=4.12-5.03) mmol/L for TC levels, 1.72(IQR=1.42-2.01) mmol/L for HDL-C levels and 1.54 (IQR=1.29-1.96) mmol/L for TGs levels. At three months, median values were: 4.38 (4.10-4.95) mmol/L for TC levels (p<0.05), 1.57(1.34-1.93) mmol/L for HDL-C levels (p<0.005) and 1.8(1.23-2.34) mmol/L for TGs levels (p<0.05). CONCLUSIONS: Median serum lipid levels remained in the normal range, despite an increasing-trend at three months of treatment with oxcarbazepine. Further studies are necessary to confirm these results.
| Titolo: | Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children. | |
| Autore/i: | FRANZONI, EMILIO; Marchiani V.; Cecconi I.; Moscano F. C.; GUALANDI, STEFANO; GARONE, CATERINA; Sarajlija J.; Malaspina E. | |
| Autore/i Unibo: | ||
| Anno: | 2006 | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/j.1468-1331.2006.01535.x | |
| Abstract: | PURPOSE: The aim of the present study was to assess serum lipid levels before and after treatment with oxcarbazepine in children with epilepsy. METHODS: We measured total cholesterol (TC), triglycerides (TGs) and high-density lipoprotein cholesterol (HDL-C) in 28 patients whereas only TC levels in 11 patients, during baseline period and at 3 months after the beginning of therapy with oxcarbazepine. RESULTS: During baseline period, median values were: 4.38 (IQR=4.12-5.03) mmol/L for TC levels, 1.72(IQR=1.42-2.01) mmol/L for HDL-C levels and 1.54 (IQR=1.29-1.96) mmol/L for TGs levels. At three months, median values were: 4.38 (4.10-4.95) mmol/L for TC levels (p<0.05), 1.57(1.34-1.93) mmol/L for HDL-C levels (p<0.005) and 1.8(1.23-2.34) mmol/L for TGs levels (p<0.05). CONCLUSIONS: Median serum lipid levels remained in the normal range, despite an increasing-trend at three months of treatment with oxcarbazepine. Further studies are necessary to confirm these results. | |
| Data prodotto definitivo in UGOV: | 2006-02-28 15:55:16 | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
http://hdl.handle.net/11585/24152
Copyright © 2022